A recent study has definitively refuted President Donald Trump's baseless claim that paracetamol causes autism. The research, published in the Lancet Obstetrics, Gynaecology and Women’s Health, analyzed 43 previous studies and found no evidence linking maternal paracetamol use during pregnancy to an increased risk of autism spectrum disorder, ADHD, or intellectual disability in children. This comprehensive review, led by Professor Asma Khalil, a renowned expert in obstetrics and maternal fetal medicine, involved a team of seven researchers from across Europe. The study's findings are particularly significant given the widespread anxiety they triggered among pregnant women, as paracetamol is a recommended pain reliever for women during pregnancy. The researchers emphasize that paracetamol remains a safe option when taken as directed, and they urge pregnant women to continue using it for symptom relief without fear of adverse effects on their children. The study's authors also address the possibility that underlying health conditions prompting paracetamol use may play a more significant role in neurodevelopmental outcomes than the drug itself. This study joins a growing body of research that refutes Trump's claims, which were widely condemned by medical, women’s health, and scientific organizations globally. Trump's statements, made during a press conference at the White House, suggested that paracetamol (known as Tylenol in the US) was dangerous and advised pregnant women to avoid it. However, the study's findings are clear: paracetamol does not increase the risk of autism or other developmental disorders in children. The research concludes that familial and genetic factors are more likely explanations for observed associations between paracetamol and developmental disorders. The study's publication in a prestigious medical journal and the positive response from health experts worldwide further reinforce the safety and efficacy of paracetamol during pregnancy, providing reassurance to expectant mothers and healthcare providers alike.
